CSF3 and Axenfeld-Rieger syndrome: Furthermore, this medication drastically improved the 30-day survival rate of mice exposed to lethal 7.25- or 7.5-Gy TBI (80%, Fig. 1e, or 60%, Fig. 1f, respectively) compared to the TBI mice, suggesting that the clinical dosage administration in combination with G-CSF and RP may have radio-mitigative effects on lethal TBI mice and can be used as a potent therapeutic agent to mitigate radiation-induced severe ARS.